Advertisement
Targeting SBP to less than 140 mm Hg led to more acute cerebral ischemia and neurologic deterioration
Patients in a single tertiary care facility who were hospitalized for primary intracerebral hemorrhage (ICH) and managed with a systolic blood pressure (SBP) target of less than 140 mm Hg developed more acute cerebral ischemia on MRI and neurologic deterioration than patients whose SBP goal was less than 160 mm Hg.
Advertisement
Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy
So finds a retrospective study with a historical controls recently published online in Neurology.
“Although high blood pressure puts a patient at risk for hemorrhagic stroke, lowering blood pressure too much right afterwards makes matters worse,” says stroke neurologist Ken Uchino, MD, Director of Research and Education in Cleveland Clinic’s Cerebrovascular Center and a senior author of the study. “This study adds to the evidence that we should not be too aggressive with lowering blood pressure following an intracerebral hemorrhage.”
The study reviewed records of 286 consecutive patients with acute primary ICH admitted to Cleveland Clinic during 2013 and 2014. In 2013, the institutional protocol was an SBP target of less than 160 mm Hg; in 2014, the target was reduced to below 140 mm Hg.
According to Dr. Uchino, the change in targets was prompted by the INTERACT2 trial, published in the New England Journal of Medicine (2013;368:2355-2365), which found that early intensive blood pressure lowering (within six hours of ICH onset) resulted in better functional outcomes. Notably different from the clinical trial, the lower blood pressure target was applied to all patients with acute ICH, regardless of time since hemorrhage onset.
To qualify for the current study, a brain MRI with diffusion-weighted imaging had to have been performed within two weeks of a patient’s admission. Those with ICH due to trauma, vascular malformations or tumors were excluded, as were patients who had emergent surgical evacuation or digital subtraction angiography prior to MRI, or if death or withdrawal of life support occurred within the first 72 hours. The inclusion criteria were met by 119 patients.
Advertisement
Patients were treated acutely with IV nicardipine, then chronically with oral medications within 24 to 72 hours of admission, to achieve the SBP targets. Nursing orders specified that the provider was to be notified for mean arterial pressures less than 65 mm Hg; no floor was specified for SBP levels.
The primary outcomes were the presence of acute cerebral ischemia on MRI and acute neurologic deterioration during hospitalization, defined as at least a 4-point increase in the NIH Stroke Scale. Two separate analyses were conducted, comparing:
Compared with patients with the higher target SBP, patients with the lower target (< 140 mm Hg) had:
Analyzing the data from the perspective of who did or didn’t develop cerebral ischemia, no significant differences in SBP were found at admission, but patients with acute cerebral ischemia had significantly lower mean SBP over the subsequent 24 hours and lower minimum SBP over 72 hours. Having an SBP below 120 mm Hg was a significant predictor of acute cerebral ischemia.
Advertisement
According to Dr. Uchino, there were good theoretical reasons for thinking that intensive blood pressure lowering should be helpful during an acute hemorrhagic stroke — that is, to stop the bleeding. But these findings, as well as those of the ATACH-2 study (N Engl J Med. 2016;375:1033-1043), call that reasoning into question.
“For most patients, bleeding into the brain has probably stopped within a few hours of the onset of the stroke,” Dr. Uchino speculates. “After that point, too little blood pressure will more likely lead to poorer outcomes from ischemia.”
Dr. Uchino says that, as a result of this study, Cleveland Clinic has instituted two changes for treating patients hospitalized with an ICH:
He adds that while this is a retrospective study from a single institution, such analyses can reveal important information and reviewing outcomes in this way is an important part of quality assurance in healthcare.
“Almost any medical therapy has potential harm as well as benefits,” he says. “Studies like this one bring us closer to finding the right balance.”
Advertisement
Advertisement
Understanding TE involvement is a key to developing new treatments
Study aims to inform an enhanced approach to exercise as medicine
$3.2 million grant will fund use of calcium-based imaging to record neuronal activity in ischemia model
New phase 1 trial showcases Neurological Institute’s interdisciplinary study capabilities
Chronic stress, asymptomatic disease affect different brains differently
Real-world claims data and tissue culture studies set the stage for randomized clinical testing
New grant-funded investigation illustrates impact and reach of Cleveland Clinic Brain Study
How the new longitudinal investigation could become the Framingham Heart Study of brain health